Lexeo Therapeutics Inc (LXEO) Stock Price, Quote & News

Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 547 9879

Website: www.lexeotx.com

Address:

345 Park Avenue South, 6th Floor, New York, United States

UgoGreg Feb. 21 at 3:57 PM

$LXEO https://youtu.be/ygBN8MilTyc

0 · Reply

OfficialStocktwitsUser Feb. 20 at 1:51 PM

$LXEO RSI: 22.92, MACD: -0.5679 Vol: 0.51, MA20: 7.09, MA50: 8.44 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MarshallStrain318 Feb. 11 at 3:48 PM

$LXEO Lexeo Therapeutics; gene therapy biotech (cardiovascular, CNS); early-stage; high-risk modality; partnered with large pharma.

0 · Reply

Aawilliam2003 Feb. 4 at 5:43 PM

$LRMR this is not trading well. Who thinks they will get the nod to file in Q2? There are several other companies making waves in this space that may complicate their efforts eg $LXEO $SLDB

2 · Reply

CandleChief Feb. 4 at 4:07 PM

$LXEO is a technology or materials company; without specifics, analysis would focus on its product cycle, competitive position, and end-market demand.

1 · Reply

MacAwoo Feb. 3 at 6:14 PM

$LXEO 🤔💭

0 · Reply

OfficialStocktwitsUser Jan. 22 at 1:55 PM

$LXEO RSI: 31.46, MACD: -0.6054 Vol: 1.29, MA20: 9.15, MA50: 9.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Night_Owl_Biotech Jan. 22 at 12:24 AM

Largest changes in share price for XBI components since 1/9/2026 (pre-JP Morgan) for entertainment purposes only. The XBI is up 3% since the event started. $CRVS posted compelling Eczema/AD data this morning $IBRX is self-evident after the NSCLC data (coupled with Q425 sales). $ERAS ? $SPRY We did not see any new PR. ARS bounced back from the $7.00 lows around Thanksgiving. $LXEO Can any LXEO bull comment on the data? The 2020 data appeared OK We focus on commercial-stage so we're only trying to learn. This is not investment advice.

2 · Reply

Aawilliam2003 Jan. 21 at 3:21 AM

$LXEO what's better for FA? LRMR or LXEO

1 · Reply

Bankstar Jan. 18 at 6:34 PM

$LXEO 👀

0 · Reply

Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 5, 2026, 7:30 AM EST - 21 days ago

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

Jan 27, 2026, 7:30 AM EST - 4 weeks ago

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Jan 14, 2026, 1:56 PM EST - 6 weeks ago

Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 12:55 PM EST - 6 weeks ago

Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Dec 22, 2025, 7:30 AM EST - 2 months ago

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 5:57 PM EST - 2 months ago

Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

Dec 4, 2025, 8:00 AM EST - 3 months ago

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Nov 6, 2025, 4:59 PM EST - 3 months ago

Lexeo Therapeutics: Behind The Rebound

Nov 5, 2025, 7:36 AM EST - 4 months ago

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Oct 20, 2025, 4:05 PM EDT - 4 months ago

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Oct 16, 2025, 11:29 PM EDT - 4 months ago

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Oct 16, 2025, 4:32 PM EDT - 4 months ago

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Oct 7, 2025, 3:22 PM EDT - 5 months ago

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback

Oct 7, 2025, 12:45 PM EDT - 5 months ago

Lexeo Therapeutics, Inc. - Special Call

Oct 7, 2025, 6:00 AM EDT - 5 months ago

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Aug 14, 2025, 7:30 AM EDT - 7 months ago

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 7, 2025, 7:00 AM EDT - 8 months ago

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Jun 24, 2025, 7:30 AM EDT - 8 months ago

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

May 27, 2025, 7:31 AM EDT - 9 months ago

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 12, 2025, 7:00 AM EDT - 10 months ago

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 5, 2025, 2:19 PM EDT - 10 months ago

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

May 1, 2025, 9:16 AM EDT - 10 months ago

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Apr 7, 2025, 9:34 AM EDT - 11 months ago

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Apr 7, 2025, 6:00 AM EDT - 11 months ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Jan 7, 2025, 7:30 AM EST - 1 year ago

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Nov 13, 2024, 7:30 AM EST - 1 year ago

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 6:14 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 16, 2024, 1:17 PM EDT - 1 year ago

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Jul 15, 2024, 12:05 PM EDT - 1 year ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

May 9, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 22, 2024, 7:30 AM EDT - 2 years ago

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Apr 9, 2024, 5:26 PM EDT - 2 years ago

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Mar 13, 2024, 4:22 PM EDT - 2 years ago

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Mar 11, 2024, 7:42 AM EDT - 2 years ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 11, 2024, 7:30 AM EDT - 2 years ago

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Feb 5, 2024, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Dec 18, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Dec 11, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 4, 2023, 12:21 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

ATGL HG IPO IPOS KVUE NCI PAPL

Nov 3, 2023, 12:39 PM EDT - 2 years ago

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

UgoGreg Feb. 21 at 3:57 PM

$LXEO https://youtu.be/ygBN8MilTyc

0 · Reply

OfficialStocktwitsUser Feb. 20 at 1:51 PM

0 · Reply

MarshallStrain318 Feb. 11 at 3:48 PM

$LXEO Lexeo Therapeutics; gene therapy biotech (cardiovascular, CNS); early-stage; high-risk modality; partnered with large pharma.

0 · Reply

Aawilliam2003 Feb. 4 at 5:43 PM

$LRMR this is not trading well. Who thinks they will get the nod to file in Q2? There are several other companies making waves in this space that may complicate their efforts eg $LXEO $SLDB

2 · Reply

CandleChief Feb. 4 at 4:07 PM

$LXEO is a technology or materials company; without specifics, analysis would focus on its product cycle, competitive position, and end-market demand.

1 · Reply

MacAwoo Feb. 3 at 6:14 PM

$LXEO 🤔💭

0 · Reply

OfficialStocktwitsUser Jan. 22 at 1:55 PM

0 · Reply

Night_Owl_Biotech Jan. 22 at 12:24 AM

2 · Reply

Aawilliam2003 Jan. 21 at 3:21 AM

$LXEO what's better for FA? LRMR or LXEO

1 · Reply

Bankstar Jan. 18 at 6:34 PM

$LXEO 👀

0 · Reply

MacAwoo Jan. 16 at 9:51 PM

$LXEO might be time for some accumulation

0 · Reply

SuperGreenToday Jan. 16 at 9:20 PM

$LXEO Share Price: $7.40 Contract Selected: Aug 21, 2026 $5 Calls Buy Zone: $0.89 – $1.10 Target Zone: $1.58 – $1.93 Potential Upside: 67% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

xsiddiqmx Jan. 13 at 10:57 PM

$LXEO closing gap nothing to see here. Up from here.

0 · Reply

Quantumup Jan. 13 at 12:20 PM

Oppenheimer reiterated $LXEO Outperform-$20 $RCKT $TNYA $LRMR $BIIB VYGR DSGN PTCT Oppenheimer said in its note: We believe yesterday's interim look from LX2020's Phase 1/2 HEROIC study in PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) yielded clear efficacy signals across the high-dose cohorts accompanied by unconcerning safety observations. With shares having closed down 23% vs. a flat XBI, the market may have been looking for a more consistent relationship between PKP2 increase and arrhythmia improvement-but we emphasize that the data remain immature, and look forward to 12-month follow-up results from all high-dose participants in 4Q26. We regard the selloff as having made the shares more attractive in view of LX2006's opportunity in Friedreich's ataxia ($1B+ US peak sales opportunity), which remains the key LXEO investor focus in our view and for which Phase 2 remains on track to begin in 1H.

1 · Reply